Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): Results from a case-control study in Ghana

Clinical Infectious Diseases

Volumn 40, Issue 10, 2005, Pages 1445-1453

  Raghunathan, Pratima L ^a,b   Whitney, Ellen A S ^a   Asamoa, Kwame ^d   Stienstra, Ymkje ^f   Taylor Jr , Thomas H ^a   Amofah, George K ^d   Ofori Adjei, David ^e   Dobos, Karen ^c   Guarner, Jeannette ^a   Martin, Stacey ^c   Pathak, Sonal ^a   Klutse, Erasmus ^d   Etuaful, Samuel ^d   Van Der Graaf, Winette T A ^f   Van Der Werf, Tjip S ^f   King, C H ^c   Tappero, Jordan W ^a   Ashford, David A ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GHANA HEALTH SERVICE   (Ghana)

^e University of Ghana   (Ghana)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BATH; BCG VACCINATION; BURULI ULCER; CHILD; CONTROLLED STUDY; FEMALE; GHANA; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSECT BITE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SKIN BIOPSY; SKIN DEFECT; STAINING;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GHANA; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS; ODDS RATIO; RISK FACTORS; SEX CHARACTERISTICS; SKIN ULCER;

EID: 20944450856     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429623     Document Type: Article

References (39)

1. Horsburgh CR, Meyers WM. Buruli ulcer. In: Horsburgh CR, Nelson AM, eds. Pathology of emerging infections. Washington, DC. American Society for Microbiology, 1997:119-34.
2. van der Werf T, Stinear T, Stienstra Y, van der Graaf W, Small P. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003; 362:1062-4.
3. Thangaraj HS, Evans MR, Wansbrough-Jones MH. Mycobacterium ulcerans disease; Buruli ulcer. Trans R Soc Trop Med Hyg 1999; 93:337-40.
4. Buruli ulcer disease. Mycobacterium ulcerans infection. Wkly Epidemiol Rec 2002; 77:271-5.
5. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999; 354:1013-8.
6. Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973; 2:873-7.
7. Espey DK, Djomand G, Diomande I, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002; 6:60-5.
8. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283:854-7.
9. Daniel AK, Lee RE, Portaels F, Small PLC. Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone. Infect Immun 2004; 72:123-32.
10. Dobos KM, Small PL, Deslauriers M, Quinn FD, King CH. Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun 2001; 69:7182-6.
11. Veitch MG, Johnson PD, Flood PE, Leslie DE, Street AC, Hayman JA. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect 1997; 119:313-8.
12. Ross BC, Johnson PD, Oppedisano F, et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol 1997; 63:4135-8.
13. Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda. Trans R Soc Trop Med Hyg 1971; 65:763-75.
14. Oluwasanmi JO, Solankee TF, Olurin EO, Itayemi SO, Alabi GO, Lucas AO. Mycobacterium ulcerans (Buruli) skin ulceration in Nigeria. Am J Trop Med Hyg 1976; 25:122-8.
15. Hayman J. Postulated epidemiology of Mycobacterium ulcerans infection. Int J Epidemiol 1991; 20:1093-8.
16. Barker DJ. Epidemiology of Mycobacterium ulcerans infection. Trans R Soc Trop Med Hyg 1973; 67:43-50.
17. Stinear T, Davies JK, Jenkin GA, Hayman JA, Oppedisano F, Johnson PD. Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl Environ Microbiol 2000; 66:3206-13.
18. Meyers WM, Connor DH, McCullough B, Bourland J, Moris R, Proos L. Distribution of Mycobacterium ulcerans infections in Zaire, including the report of new foci. Ann Soc Belg Med Trop 1974; 54:147-57.
19. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 1999; 353:986.
20. Marston BJ, Diallo MO, Horsburgh CR Jr, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am J Trop Med Hyg 1995; 52:219-24.
21. Barker DJP, Ninikibigaya V. Buruli disease and patients' activities. East Afr Med J 1972; 49:260-8.
22. Amofah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 2002; 8:167-70.
23. Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: World Health Organization, 2000:118.
24. Portaels F, Johnson P, Meyers WM. Buruli ulcer: diagnosis of Mycobacterium' ulcerans disease, a manual for health care providers. Geneva: World Health Organization, 2001:92
25. Guarner J, Bartlett J, Whitney E, et al. Histopathologic features of Buruli ulcer infection. Emerg Infect Dis 2003; 9:651-6.
26. King C, Ashford D, Dobos K, et al. Mycobacterium ulcerans infection and Buruli ulcer disease: emergence of a public health dilemma. In: Scheld WM, Craig WA, Hughes JM, eds. Emerging infections. Vol. 5. Washington, DC: ASM Press, 2001:137-52.
27. Stienstra Y, van der Werf TS, Guarner J, et al. Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic. J Clin Microbiol 2003; 41:794-7.
28. Guimaraes-Peres A, Portaels F, de Rijk P, et al. Comparison of two PCRs for detection of Mycobacterium ulcerans. J Clin Microbiol 1999; 37:206-8.
29. Kanga JM, Kacou ED. Epidemiological aspects of Buruli ulcer in Cote d'Ivoire: results of a national survey [in French]. Bull Soc Pathol Exot 2001; 94:46-51.
30. Barker DJ, Carswell JW. Mycobacterium ulcerans infection among tsetse control workers in Uganda. Int J Epidemiol 1973; 2:161-5.
31. Marsollier L, Stinear T, Aubry J, et al. Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment. Appl Environ Microbiol 2004; 70:1097-103.
32. Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002; 68:4623-8.
33. Ponnighaus JM, Fine PE, Sterne JA, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in Northern Malawi. Lancet 1992; 339:636-9.
34. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer): first results of a trial in Uganda. Lancet 1969; 1:111-5.
35. Smith PG, Revill WDL, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 1976; 70:449-57.
36. Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62-5.
37. Darie H, Le Guyadec T, Touze JE. Epidemiological and clinical aspects of Buruli ulcer in Ivory Coast: 124 recent cases [in French]. Bull Soc Pathol Exot 1993; 86:272-6.
38. Darie H, Cautoclaud A, Lajaunie C, Millet P. Dermatological aspects of AIDS in western Africa: apropos of 140 cases [in French]. Bull Soc Pathol Exot 1994; 87:176-80.
39. Delaporte E, Alfandari S, Piette F. Mycobacterium ulcerans associated with infection due to the human immunodeficiency virus. Clin Infect Dis 1994; 18:839.